BioCentury
ARTICLE | Finance

Merging for an IPO

U.S.-Swiss merger by Horizon, Nitec aims to provide access to U.S. IPO market

April 12, 2010 7:00 AM UTC

By combining one marketed drug and regulatory filings in the queue in both the U.S. and Europe, Illinois-based Horizon Therapeutics Inc. and Swiss biotech Nitec Pharma AG believe their merger has created the de-risked profile that investors want to see in an IPO.

The newco, Horizon Pharma Inc., will focus on pain and inflammation...